Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates
Saunders KO, Pardi N, Parks R, Santra S, Mu Z, Sutherland L, Scearce R, Barr M, Eaton A, Hernandez G, Goodman D, Hogan MJ, Tombacz I, Gordon DN, Rountree RW, Wang Y, Lewis MG, Pierson TC, Barbosa C, Tam Y, Shen X, Ferrari G, Tomaras GD, Montefiori DC, Weissman D, Haynes BF.
Darunavir/cobicistat is associated with negative outcomes in HIV-negative patients with severe COVID-19 pneumonia
Milic J, Novella A, Meschiari M, Menozzi M, Santoro A, Bedini A, Cuomo G, Franceschini E, Digaetano M, Carli F, Ciusa G, Volpi S, Bacca E, Franceschi G, Yaacoub D, Rogati C, Tutone M, Burastero G, Faltoni M, Iadisernia V, Dolci G, Cossarizza A, Mussini C, Pasina L, Guaraldi G.
Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort
Nasreddine R, Florence E, Moutschen M, Yombi JC, Goffard JC, Derdelinckx I, Lacor P, Vandekerckhove L, Messiaen P, Vandecasteele S, Delforge M, De Wit S; Belgian Research on AIDS and HIV Consortium (BREACH).
Preparedness of health facilities providing HIV services during COVID-19 pandemic and assessment of their compliance to COVID-19 prevention measures: findings from the Tanzania Service Provision Assessment (SPA) survey
Incidence and Outcomes of COVID-19 in Kidney and Liver Transplant Recipients With HIV: Report From the National HOPE in Action Consortium
Mehta SA, Rana MM, Motter JD, Small CB, Pereira MR, Stosor V, Elias N, Haydel B, Florman S, Odim J, Morsheimer M, Robien M, Massie AB, Brown D, Boyarsky B, Garonzik Wang J, Tobian AAR, Werbel WA, Segev DL, Durand CM; HOPE in Action Investigators..
Exploring anti-corruption, transparency, and accountability in the World Health Organization, the United Nations Development Programme, the World Bank Group, and the Global Fund to Fight AIDS, Tuberculosis and Malaria
Innovations in HIV care delivery during the COVID-19 pandemic: Policies to strengthen the Ending the Epidemic Initiative - A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association
Armstrong WS, Agwu AL, Barrette EP, Ignacio RB, Chang JJ, Colasanti JA, Floris-Moore M, Haddad M, MacLaren L, Weddle A.
Substantial decline in use of HIV pre-exposure prophylaxis (PrEP) following introduction of COVID-19 physical distancing restrictions in Australia: Results from a prospective observational study of gay and bisexual men
Hammoud MA, Grulich A, Holt M, Maher L, Murphy D, Jin F, Bavinton B, Haire B, Ellard J, Vaccher S, Saxton P, Bourne A, Degenhardt L, Storer D, Prestage G.
Clinical characteristics, risk factors, and incidence of symptomatic COVID-19 in adults living with HIV: a single-center, prospective observational study
Inciarte A, Gonzalez-Cordon A, Rojas J, Torres B, de Lazzari E, de la Mora L, Martinez-Rebollar M, Laguno M, Callau P, Gonzalez-Navarro A, Leal L, Garcia F, Mallolas J, Mosquera M, Marcos MA, Ambrosioni J, Miro JM, Martinez E, Blanco JL; (on behalf the COVID-19 in HIV Investigators).
Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models
Jewell BL, Mudimu E, Stover J, Ten Brink D, Phillips AN, Smith JA, Martin-Hughes R, Teng Y, Glaubius R, Mahiane SG, Bansi-Matharu L, Taramusi I, Chagoma N, Morrison M, Doherty M, Marsh K, Bershteyn A, Hallett TB, Kelly SL; HIV Modelling Consortium.
Conducting rapid qualitative research to support sex workers' health and social needs in the face of COVID-19: capitalising on stakeholder networks from the HIV response in Singapore to drive policymaking
Tan RKJ, Lim JM, Lo JJ, Teo AKJ, O'Hara CA, Ching AH, Ho V, Wong ML.
Economic, Mental Health, HIV Prevention and HIV Treatment Impacts of COVID-19 and the COVID-19 Response on a Global Sample of Cisgender Gay Men and Other Men Who Have Sex with Men
Santos GM, Ackerman B, Rao A, Wallach S, Ayala G, Lamontage E, Garner A, Holloway IW, Arreola S, Silenzio V, Str√∂mdahl S, Yu L, Strong C, Adamson T, Yakusik A, Doan TT, Huang P, Cerasuolo D, Bishop A, Noori T, Pharris A, Aung M, Dara M, Chung SY, Hanley M, Baral S, Beyrer C, Howell S.
The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections.
Musarrat F, Chouljenko V, Dahal A, Nabi R, Chouljenko T, Jois SD, Kousoulas KG.